| 期刊簡介 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | JOURNAL OF EXPERIMENTAL MEDICINE LetPub Score 9.2
50 ratings
Rate
Reputation 10.0 Influence 9.0 Speed 7.1 | ||||||||||||||||||||
| 期刊簡稱 | J EXP MED | ||||||||||||||||||||
| ISSN | 0022-1007 | ||||||||||||||||||||
| E-ISSN | 1540-9538 | ||||||||||||||||||||
| h-index | 411 | ||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||
| 自引率 (2023-2024) | 1.60%自引率趨勢 | ||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||
| 官方網站 | http://jem.rupress.org/ | ||||||||||||||||||||
| 在線稿件提交 | http://jem.rupress.org/site/misc/submit.xhtml | ||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||
| 出版商 | Rockefeller University Press | ||||||||||||||||||||
| 主題領域 | 医学 | ||||||||||||||||||||
| 出版國/地區 | UNITED STATES | ||||||||||||||||||||
| 發行頻率 | 月2回刊行 | ||||||||||||||||||||
| 創刊年 | 1896 | ||||||||||||||||||||
| 每年文章數 | 171每年文章數趨勢 | ||||||||||||||||||||
| 黃金OA百分比 | 43.04% | ||||||||||||||||||||
| Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Science Citation Index Expanded | ||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0022-1007%5BISSN%5D | ||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Ordinary, 3-8 Week(s) | ||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Very difficult | ||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||
| *所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 2 下一頁 末頁 (頁 | |
| [JOURNAL OF EXPERIMENTAL MEDICINE] 的評論 | 撰寫評論 |
| 作者: 斯羽酱吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-05-06 17:48:12 評論於 Congratulations! How many reviewers were there at that time? |
| 作者: Nigel Frederick 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-04-21 22:04:01 評論於 Hello, may I ask about your experience in submitting articles to JEM? Would you be willing to discuss it privately? |
| 作者: 筑阳婵娟 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-10-08 18:13:08 評論於 Review speed: 1.0 | Submission acceptance rate: 25.0 Sharing of experience: First review takes one month, just for your reference |
| 作者: 云来又容 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-09-08 19:47:49 評論於 11.99 185****0357 No nickname 2017-06-15: SCI(2015):11.24 SCI(2014):12.515 JEM IF all the way down. Lower than NC, the magazine's publishing concept is not right-- too focused on the immunology field. But without those big group sub-journals, it will continue to be unattractive. It is not impossible for JCB, another old magazine from the same publishing house, to fall a lot as well |
| 作者: 削月以松 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-06-15 13:42:42 評論於 JEM's IF is declining all the way, lower than NC. The editorial idea of the magazine is wrong... too focused on the immune field, but without the attractiveness of those large group's sub magazines. If this continues, it is not impossible for another old magazine from the same publishing house, JCB, to fall significantly as well |
| 作者: 千蕊少女 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-04-20 23:35:20 評論於 It's too hard for a professional in the field of immunology |
| 作者: 白骨含冬 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-01-09 17:16:15 評論於 Review Speed: 6.0 | Acceptance Rate: 5.0 Experience Sharing: It is difficult for papers submitted from mainland China to be accepted, and they are often rejected |
| 作者: 白骨含冬 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-12-09 21:47:45 評論於 Review speed: 2.0 | Submission hit rate: 5.0 Experience sharing: In recent years, we have also started accepting research papers other than immunology. Nature Medicine was rejected, and it was directly submitted to JEM. Submitted in March, revised once in the middle, and accepted at the end of November |
| 作者: 小野寺心慈 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2014-05-02 16:26:42 評論於 In terms of bias immunization, acceptance is very difficult |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2010-11-06 18:10:50 評論於 |
| 首頁 上一頁 1 2 下一頁 末頁 (頁 | |
Contact us